Clinical and Prognostic Factors Associated With Survival in Mexican Patients With Idiopathic Inflammatory Myopathies

被引:15
|
作者
Shunashy Galindo-Feria, Angeles [1 ]
Rojas-Serrano, Jorge [2 ,3 ]
Hinojosa-Azaola, Andrea [1 ]
机构
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Immunol & Rheumatol, Vasco de Quiroga 15,Secc 16, Mexico City 14000, DF, Mexico
[2] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Interstitial Lung Dis Unit, Mexico City, DF, Mexico
[3] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Rheumatol Unit, Mexico City, DF, Mexico
关键词
dermatomyositis; polymyositis; prognostic factors; survival; INTERSTITIAL LUNG-DISEASE; ONSET POLYMYOSITIS DERMATOMYOSITIS; LONG-TERM SURVIVAL; AMYOPATHIC DERMATOMYOSITIS; LABORATORY FEATURES; ADULT POLYMYOSITIS; UNITED-STATES; RISK-FACTORS; MORTALITY; MYOSITIS;
D O I
10.1097/RHU.0000000000000365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Factors associated with survival in patients with idiopathic inflammatory myopathies are heterogeneous. Objective This study aimed to describe clinical and prognostic factors associated with survival in Mexican patients with idiopathic inflammatory myopathies. Methods Patients with dermatomyositis (DM) and polymyositis (PM) seen at a tertiary care center from 1985 to 2012 were included. Demographic and clinical characteristics, comorbidities, treatment, and the time to death were recorded. Patients with juvenile DM were excluded. Univariate and multivariate analyses were performed to identify factors associated with mortality. Results A total of 264 patients with DM and 69 patients with PM were studied. Patients with DM had lower levels of creatine phosphokinase, less cumulative dose of prednisone, higher frequency of dysphagia, and no difference in frequency of interstitial lung disease compared with patients with PM. Patients with DM had lower survival during the first 4 years of disease (80%; 95% confidence interval [CI], 0.74-0.85 vs 89%; 95% CI, 0.78-0.95; P = 0.03 log-rank). Respiratory failure due to pulmonary infection was the main cause of death in patients with DM; miscellaneous causes were responsible for death in patients with PM. Muscular strength (hazard ratio [HR], 0.48; 95% CI, 0.27-0.83; P = 0.01), platelet count (HR, 0.98; 95% CI, 0.98-0.99; P = 0.002), as well as ever use of methotrexate (HR, 0.21; 95% CI, 0.07-0.65; P = 0.007) and azathioprine (HR, 0.21; 95% CI, 0.06-0.68; P = 0.009) were independent factors associated with mortality in patients with DM; in those with PM, only cancer was associated (HR, 8.0; 95% CI, 1.4-43.9; P = 0.01). Conclusions Patients with DM had lower survival during the first 4 years of disease than patients with PM. Factors associated with mortality differed in both groups.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 50 条
  • [31] Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies
    HausmanowaPetrusewicz, I
    KowalskaOledzka, E
    Miller, FW
    JarzabekChorzelska, M
    Targoff, IN
    BlaszczykKostanecka, M
    Jablonska, S
    ARTHRITIS AND RHEUMATISM, 1997, 40 (07): : 1257 - 1266
  • [32] How I treat idiopathic patients with inflammatory myopathies in the clinical practice
    Cavagna, Lorenzo
    Monti, Sara
    Caporali, Roberto
    Gatto, Mariele
    Iaccarino, Luca
    Doria, Andrea
    AUTOIMMUNITY REVIEWS, 2017, 16 (10) : 999 - 1007
  • [33] The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies
    Cavazzana, Ilaria
    Fredi, Micaela
    Selmi, Carlo
    Tincani, Angela
    Franceschini, Franco
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2017, 52 (01) : 88 - 98
  • [34] The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
    Shah, Mona
    Mamyrova, Gulnara
    Targoff, Ira N.
    Huber, Adam M.
    Malley, James D.
    Rice, Madeline Murguia
    Miller, Frederick W.
    Rider, Lisa G.
    MEDICINE, 2013, 92 (01) : 25 - 41
  • [35] Clinical trials roundup in idiopathic inflammatory myopathies
    Mann, Herman F.
    Vencovsky, Jiri
    CURRENT OPINION IN RHEUMATOLOGY, 2011, 23 (06) : 605 - 611
  • [36] Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Efficacy and Predictive Factors for Clinical Response
    Barsotti, Simone
    Cavazzana, Ilaria
    Neri, Rossella
    Locatelli, Francesco
    Taraborelli, Mara
    Cioffi, Elisa
    Chiapparoli, Ilaria
    Tincani, Angela
    Franceschini, Franco
    Mosca, Marta
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [37] Clinical presentation and therapy of idiopathic inflammatory myopathies
    Miller, FW
    JOURNAL OF MUSCULOSKELETAL PAIN, 2004, 12 (3-4): : 85 - 91
  • [38] The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies
    Ilaria Cavazzana
    Micaela Fredi
    Carlo Selmi
    Angela Tincani
    Franco Franceschini
    Clinical Reviews in Allergy & Immunology, 2017, 52 : 88 - 98
  • [39] Recent clinical trials in idiopathic inflammatory myopathies
    Leclair, Valerie
    Lundberg, Ingrid E.
    CURRENT OPINION IN RHEUMATOLOGY, 2017, 29 (06) : 652 - 659
  • [40] Long-term prognosis and survival of patients with idiopathic inflammatory myopathies in Hungary
    Danko, K
    Ponyi, A
    Constantin, T
    Borgulya, G
    Szegedi, G
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 303 - 303